Send to

Choose Destination
Pancreas. 2018 Nov/Dec;47(10):1244-1248. doi: 10.1097/MPA.0000000000001169.

A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Author information

Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN.
Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA.
Division of Research, Kaiser Permanente Northern California, Oakland, CA.
Division of Gastroenterology, Baylor College of Medicine, Houston, TX.
Division of Gastroenterology, The Ohio State University Wexner Medical Center, Columbus, OH.
Department of Surgery, College of Medicine, University of Florida Health Science Center, Gainesville, FL.
Division of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA.
Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA.
Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
Division of Cancer Prevention, National Cancer Institute, Rockville, MD.


The National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases initiated the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) in 2015 (the CPDPC's origin, structure, governance, and research objectives are described in another article in this journal). One of the key objectives of CPDPC is to assemble a cohort of 10,000 subjects 50 years or older with new-onset diabetes, called the NOD cohort. Using a define, enrich, and find early detection approach, the aims of the NOD study are to (a) estimate the 3-year probability of pancreatic ductal adenocarcinoma (PDAC) in NOD (define), (b) establish a biobank of clinically annotated biospecimens from presymptomatic PDAC and control new-onset type 2 diabetes mellitus subjects, (c) conduct phase 3 validation studies of promising biomarkers for identification of incident PDAC in NOD patients (enrich), and (d) provide a platform for development of a future interventional screening protocol for early detection of PDAC in patients with NOD that incorporates imaging studies and/or clinical algorithms (find). It is expected that 85 to 100 incidences of PDAC will be diagnosed during the study period in this cohort of 10,000 patients.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center